Cart
sales@molnova.com
5-Methoxyuridine
CAS No. 35542-01-9
5-Methoxyuridine( —— )
Catalog No. M37879 CAS No. 35542-01-9
5-Methoxyuridine (Mo5U) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | 28 | In Stock |
|
| 500MG | 44 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5-Methoxyuridine
-
NoteResearch use only, not for human use.
-
Brief Description5-Methoxyuridine (Mo5U) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis.
-
Description5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number35542-01-9
-
Formula Weight274.23
-
Molecular FormulaC10H14N2O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.?
molnova catalog
related products
-
PDK4-IN-1 hydrochlor...
PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4, IC50 value = 84 nM).
-
SCFSkp2-IN-2
SCFSkp2-IN-2, a Skp2 inhibitor, exhibits a dissociation constant (K_D) of 28.77 μM. It demonstrates antitumor activities by inducing apoptosis in non-small cell lung cancer (NSCLC) cells.
-
TJ08
TJ08 is a 1,2,5-trisubstituted benzimidazole derivative with anticancer properties that effectively induces G1/S phase blockade while promoting apoptotic effects in a variety of cancer cells.
